Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study

• Published in: Biomedicines Vol. 10; no. 7; p. 1657
• Main Authors: De Novellis, Danilo, Fontana, Raffaele, Carobene, Angela, Serio, Bianca, Ferrara, Idalucia, Martorelli, Maria Carmen, Mettivier, Laura, Guariglia, Roberto, Luponio, Serena, Ruggiero, Immacolata, D’Addona, Matteo, Di Leo, Tiziana, Giudice, Valentina, Selleri, Carmine
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 10.07.2022; MDPI
• Subjects: Autografts; Biomarkers; Chemotherapy; Differential diagnosis; free light chains; free light-chain ratio; Glomerular filtration rate; Hematology; Kidneys; Light; Multiple myeloma; Patients; Plasma; prognosis; Proteins; Renal failure; Stem cell transplantation; Transplants & implants; Variance analysis; United States > US; Italy
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10071657

The serum free light-chain (FLC) ratio is a sensitive tool for the differential diagnosis of plasma cell disorders and is biomarker of multiple myeloma (MM) progression from premalignant conditions. Here, we investigate the potential role of FLC ratio at diagnosis in identifying early renal damage in MM patients and other correlations with clinical, laboratory, and molecular findings. A total of 34 MM patients who had undergone autologous stem cell transplantation were included in this retrospective case series study, and FLC quantification was performed with nephelometric assays. In our study, sFLC ratio was significantly associated with light-chain MM and β-2 microglobulin levels, likely indicating a high disease burden at diagnosis, especially in patients without heavy chain M-protein at serum electrophoresis. Moreover, the sFLC ratio was inversely correlated with glomerular filtration rate, possibly identifying early renal damage in MM patients. Our preliminary results confirm the importance of early sFLC evaluation, especially in patients with the light-chain MM type and low disease burden, to minimize the risk of late renal failure.